Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: Prospective results from the EMAS

Summary Objective Limited evidence supports the use of free testosterone (FT) for diagnosing hypogonadism when sex hormone–binding globulin (SHBG) is altered. Low total testosterone (TT) is commonly encountered in obesity where SHBG is typically decreased. We aimed to assess the contribution of FT i...

Full description

Saved in:
Bibliographic Details
Published inClinical Endocrinology Vol. 89; no. 4; pp. 459 - 469
Main Authors Giulia, Rastrelli, Terence W, O'Neill, Tomas, Ahern, György, Bártfai, Felipe F, Casanueva, Gianni, Forti, Brian, Keevil, Aleksander, Giwercman, Thang S, Han, Jolanta, Slowikowska-Hilczer, Michael E J, Lean, Neil, Pendleton, Margus, Punab, Leen, Antonio, Jos, Tournoy, Dirk, Vanderschueren, Mario, Maggi, Ilpo T, Huhtaniemi, Frederick C W, Wu, Min, Jiang
Format Journal Article
LanguageEnglish
Published England Wiley 01.10.2018
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0300-0664
1365-2265
1365-2265
DOI10.1111/cen.13756

Cover

More Information
Summary:Summary Objective Limited evidence supports the use of free testosterone (FT) for diagnosing hypogonadism when sex hormone–binding globulin (SHBG) is altered. Low total testosterone (TT) is commonly encountered in obesity where SHBG is typically decreased. We aimed to assess the contribution of FT in improving the diagnosis of symptomatic secondary hypogonadism (SH), identified initially by low total testosterone (TT), and then further differentiated by normal FT (LNSH) or low FT (LLSH). Design Prospective observational study with a median follow‐up of 4.3 years. Patients Three thousand three hundred sixty‐nine community‐dwelling men aged 40‐79 years from eight European centres. Measurements Subjects were categorized according to baseline and follow‐up biochemical status into persistent eugonadal (referent group; n = 1880), incident LNSH (eugonadism to LNSH; n = 101) and incident LLSH (eugonadism to LLSH; n = 38). Predictors and clinical features associated with the transition from eugonadism to LNSH or LLSH were assessed. Results The cumulative incidence of LNSH and LLSH over 4.3 years was 4.9% and 1.9%, respectively. Baseline obesity predicted both LNSH and LLSH, but the former occurred more frequently in younger men. LLSH, but not LNSH, was associated with new/worsened sexual symptoms, including low desire [OR = 2.67 (1.27‐5.60)], erectile dysfunction [OR = 4.53 (2.05‐10.01)] and infrequent morning erections [OR = 3.40 (1.48‐7.84)]. Conclusions These longitudinal data demonstrate the importance of FT in the diagnosis of hypogonadism in obese men with low TT and SHBG. The concurrent fall in TT and FT identifies the minority (27.3%) of men with hypogonadal symptoms, which were not present in the majority developing low TT with normal FT.
Bibliography:Funding information
The European Male Aging Study is funded by the Commission of the European Communities Fifth Framework Program “Quality of Life and Management of Living Resources” Grant QLK6‐CT‐2001‐00258 and facilitated by the Manchester Biomedical Research Centre and the NIHR Greater Manchester: Clinical Research Network. Additional support was also provided by Arthritis Research UK and the National Institute for Health Research and the Manchester Musculoskeletal Biomedical Research Centre. The Principal Investigator of EMAS is Professor Frederick Wu, MD; Andrology Research Unit, University of Manchester, Manchester, UK. Prof. Dirk Vanderschueren is a senior clinical investigator supported by the Clinical Research Fund of the University Hospitals Leuven, Belgium.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0300-0664
1365-2265
1365-2265
DOI:10.1111/cen.13756